Clinical trials: Non Alcoholic Fatty Liver Disease
Diabetes, Fatty Liver
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
Background: Vitamin E is an antioxidant that reduces the damaging effects of oxygen in the body. Most American men (90%) and women (96%) do not get enough vitamin E from their diets; however, the amount of vitamin E needed by the…
- Conditions
- Diabetes, Fatty Liver, Obesity, Healthy Volunteers
- Trial name
- NCT00862433
- Testing
- Alpha tocopherol, Vitamin E, Vitamin C
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non Alcoholic Fatty Liver Disease
Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered Epeleuton capsules versus placebo in the treatment of adult patients with Non…
- Trial name
- NCT02941549
- Testing
- Epeleuton
- Where
- 16 sites in Georgia, Ukraine and 1 more
- Volunteers
- 96 people
- Sponsor
- Afimmune
Non Alcoholic Fatty Liver Disease
Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH
Recent epidemiological studies in France showed a high prevalence of obesity (14.5%) and its strong increase in the last 20 years.
- Trial name
- NCT02820285
- Testing
- Evaluation of the staging of fibrosis liver, Determine the expression level of semaphorin, Determination of the composition of immunity cells
- Where
- France
- Volunteers
- 148 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Non.Alcoholic Fatty Liver Disease
Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disorders characterized by predominantly macrovesicular hepatic steatosis occurring in individuals in the absence of significant alcohol consumption.
- Trial name
- NCT01623024
- Testing
- Vitamin D, Lifestyle counseling
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Palermo
NAFLD, Obesity
Biomarkers in the Diagnosis and Prognosis of NAFLD
Fibrosis is considered the leading cause of liver diseases and related mortality. Specifically, hepatic fibrosis is regarded as the consequence of reparative mechanisms initiated by hepatocytes in response to chronic damage.
- Conditions
- NAFLD, Obesity, Liver Fibrosis, Diabetes Mellitus, Type 2
- Trial name
- NCT06098417
- Testing
- Plasma Test, Liver biopsy, Visceral adipose tissue biopsy
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University of Trieste
HCC, Cirrhosis, Liver
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)
The objective of this observational study is to evaluate the clinical utility of the combined assay of 3 biomarkers: α-FP, α-FP-L3 and DCP (simultaneously measured by µTASWakoTM i30 automated in vitro diagnostic system) in…
- Conditions
- HCC, Cirrhosis, Liver, NAFLD, HBV
- Trial name
- GALAD (NCT05781568)
- Testing
- Biomarker dosage
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Fatty Liver, Fatty Liver, Nonalcoholic
Quantitative US for Evaluation of Hepatic Steatosis in NAFLD
The purpose of this study is to evaluate diagnostic performance of quantitative ultrasonographic parameters for the assessment of hepatic steatosis with find optimal cut-off values in patients with non-alcoholic fatty liver…
- Trial name
- NCT04462562
- Testing
- Quantitative US (Samsung Medison, RS85A)
- Where
- South Korea
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Non-Alcoholic Fatty Liver Disease
Interval Training Versus Electro Acupuncture on Liver Functions in Patients With Non-alcoholic Fatty Liver Disease
in this study, the investigators compare the effect of interval training exercise and electroacupuncture on liver functions in non-alcoholic fatty liver disease patients
- Trial name
- NCT03936803
- Testing
- aerobic interval training exercise ., electro acupuncture
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
Effect of Dietary Macronutrient Composition
The purpose of this study is to understand why Hispanics who are overweight have a higher incidence of fatty liver disease.
- Conditions
- Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01371396
- Testing
- Low-fat diet, Low-carbohydrate diet
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Vascular Stiffness, Liver Fibroses
Evaluation of the Effect of IHHT on Vascular Stiffness and Elasticity of the Liver Tissue in Patients With MS.
The aim of this study is to assess the effect of interval hypoxy-hyperoxic training (IHHT) on the arterial stiffness and elasticity of the liver tissue in patients with metabolic syndrome and on other components of the metabolic…
- Conditions
- Vascular Stiffness, Liver Fibroses, Metabolic Syndrome, Trimethylamine N-oxyde
- Trial name
- NCT04791397
- Testing
- Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy., Simulating Interval hypoxic-hyperoxic training (IHHT) using respiratory therapy unit ReOxy.
- Where
- Russia
- Volunteers
- 62 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT03459079
- Testing
- Lanifibranor
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Florida
Non-alcoholic Fatty Liver Disease
Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
The study is designed to assess the safety and efficacy of different doses and dosing regimens of Runihol, tablets, enteric coated, produced by "NTFF" POLYSAN" (Russia), in prevention of liver disease progression in patients with…
- Trial name
- NCT02930161
- Testing
- Runihol
- Where
- 3 sites in Russia
- Volunteers
- 35 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Nonalcoholic Fatty Liver Disease
Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD
This is a randomised clinical trial which aims to evaluate the efficacy of Compound Zhenzhu Tiaozhi capsules in the treatment of NAFLD and analyze the relationship between improvement in NAFLD parameters and changes in intestinal…
- Trial name
- NCT03375580
- Testing
- TLC, metformin, Compound Zhenzhu Tiaozhi capsule
- Where
- China
- Volunteers
- 196 people
- Sponsor
- The First Affiliated Hospital of Guangdong Pharmaceutical University
Nonalcoholic Steatohepatitis, Liver Diseases
Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
The purpose of this study is to explore the potential benefit of the medication, pentoxifylline, for the treatment of NASH.
- Trial name
- NCT00267670
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Northwestern University
Non-Alcoholic Fatty Liver Disease
Investigation on Safety and Efficacy of Soybean Fermented Extract (MBS217) in Treating Patients With NAFLD
Investigators aimed to investigate the efficacy and safety of fermented soybean extract (MBS-217) in treating participants with Non-alcoholic fatty liver disease (NAFLD) in this study.
- Trial name
- NCT05686174
- Testing
- MBS217
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
NASH, MASH
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)
This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin [softgel] capsule) for 12 weeks.
- Conditions
- NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
- Trial name
- HERALD (NCT06342947)
- Testing
- ALG-055009
- Where
- 40 sites in United States
- Volunteers
- 102 people
- Sponsor
- Aligos Therapeutics
Non-Alcoholic Fatty Liver Disease
Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the global population and causes serious complications, including cirrhosis, hepatocellular carcinoma or mortality.
- Trial name
- NCT05754385
- Testing
- Ambulatory monitoring of liver fat, Standard of care
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The University of Hong Kong
Insulin Resistance, Hyperinsulinemia
Effect of Alpelisib in Healthy Volunteers
The goal of this clinical trial is to test a single dose of the phosphoinositide-3-kinase (PI3K) inhibitor alpelisib versus placebo in healthy volunteers.
- Conditions
- Insulin Resistance, Hyperinsulinemia, Dyslipidemias
- Trial name
- NCT05733455
- Testing
- Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Columbia University
Nonalcoholic Steatohepatitis
Betaine in Patients With Nonalcoholic Steatohepatitis
To assess the safety and efficacy of betaine in patients with NASH on markers of disease severity such as liver histology, liver biochemistries, and health related quality of life.
- Trial name
- NCT00586911
- Testing
- Cystadane
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Mayo Clinic
Nonalcoholic Fatty Liver Disease, Metabolic-associated Fatty Liver Disease
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease.
- Trial name
- NCT07149571
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.